Clozapine treatment and risk of COVID-19.
Published version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Osimo, Emanuele F https://orcid.org/0000-0001-6239-5691
Lewis, Jonathan
Cardinal, Rudolf https://orcid.org/0000-0002-8751-5167
Khandaker, Golam M
Abstract
The antipsychotic clozapine is known to have immune-modulating effects. Clozapine treatment has been reported to be associated with increased risk of COVID-19 infection. However, it remains unclear whether this is because of increased testing of this patient group, who are closely monitored. We linked anonymised health records from mental health services in Cambridgeshire (UK), for patients taking antipsychotic medication, with data from the local COVID-19 testing hub. Patients receiving clozapine were more likely to be tested for COVID-19, but not to test positive. Increased testing in patients receiving clozapine suggests prudent judgement by clinicians, considering the overall health vulnerabilities of this group.
Description
Keywords
Antipsychotics, COVID-19, clozapine, psychotic disorders, schizophrenia
Journal Title
BJPsych Open
Conference Name
Journal ISSN
2056-4724
2056-4724
2056-4724
Volume Title
8
Publisher
Royal College of Psychiatrists
Publisher DOI
Sponsorship
Wellcome Trust (201486/Z/16/Z)
Medical Research Council (MC_PC_17213)
MQ: Transforming Mental Health (MQDS17\40)
Medical Research Council (MR/S037675/1)
National Institute for Health Research (IS-BRC-1215-20014)
MRC (via Swansea University) (DATAMIND 106893)
Medical Research Council (MC_PC_17213)
MQ: Transforming Mental Health (MQDS17\40)
Medical Research Council (MR/S037675/1)
National Institute for Health Research (IS-BRC-1215-20014)
MRC (via Swansea University) (DATAMIND 106893)